Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GNRHR | P30968 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26187097 | 0.94 | USP30 (0.56) | USP30KDM4EPKMGNRHRGPR119 | |
| SCHEMBL27391745 | 0.90 | USP30 (0.52) | USP30KDM4EPKMGNRHRGPR119 | |
| SCHEMBL1363539 | 0.88 | USP30 (0.48) | USP30KDM4EPKMGNRHRGPR119 | |
| SCHEMBL29132274 | 0.85 | GPR119 (0.48) | USP30GNRHRGPR119FAAH | |
| SCHEMBL31697000 | 0.85 | USP30 (0.52) | USP30GPR119TP53 | |
| SCHEMBL16491260 | 0.85 | USP30 (0.54) | USP30GPR119FAAH | |
| SCHEMBL16014969 | 0.84 | USP30 (0.51) | USP30KDM4EPKMGPR119 | |
| SCHEMBL22738206 | 0.84 | KMT2A (0.44) | LMNAFAAH | |
| SCHEMBL23329734 | 0.83 | USP30 (0.50) | USP30KDM4EPKMGPR119FAAH | |
| SCHEMBL180435 | 0.83 | USP30 (0.56) | USP30KDM4EGPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-118344370-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-105418632-B | Thienopyrimidine derivative, preparation method and medical application thereof | 上海创诺医药集团有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| EP-2964635-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-05-02 | — | — | EP | disclosed |
| EP-3310773-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016205590-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| WO-2016041201-A1 | THIENOPYRIMIDINE DERIVATIVES AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | 上海创诺医药集团有限公司 | 2016-03-24 | — | — | WO | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| WO-2010048149-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | USP30 2363/4885KDM4E 536/4885PKM 920/4885 |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | USP30 2363/4885KDM4E 536/4885PKM 920/4885 |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | FASN, FADS1, ASS1 | USP30 3642/4885KDM4E 737/4885PKM 2162/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | USP30 81/4885KDM4E 1445/4885PKM 4009/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | USP30 81/4885KDM4E 1445/4885PKM 4009/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | USP30 81/4885KDM4E 2261/4885PKM 4711/4885 |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | USP30 81/4885KDM4E 1445/4885PKM 4009/4885 |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | USP30 2855/4885KDM4E 1504/4885PKM 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.